
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Venus Concept Inc (VERO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VERO (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $10.6
1 Year Target Price $10.6
0 | Strong Buy |
0 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -79.37% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.54M USD | Price to earnings Ratio - | 1Y Target Price 10.6 |
Price to earnings Ratio - | 1Y Target Price 10.6 | ||
Volume (30-day avg) 1 | Beta 0.12 | 52 Weeks Range 2.10 - 10.12 | Updated Date 08/14/2025 |
52 Weeks Range 2.10 - 10.12 | Updated Date 08/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -71.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -81.26% | Operating Margin (TTM) -69.84% |
Management Effectiveness
Return on Assets (TTM) -24.36% | Return on Equity (TTM) -463.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 39952442 | Price to Sales(TTM) 0.07 |
Enterprise Value 39952442 | Price to Sales(TTM) 0.07 | ||
Enterprise Value to Revenue 0.66 | Enterprise Value to EBITDA -3.16 | Shares Outstanding 1859120 | Shares Floating 1244544 |
Shares Outstanding 1859120 | Shares Floating 1244544 | ||
Percent Insiders 0.82 | Percent Institutions 14.16 |
Upturn AI SWOT
Venus Concept Inc

Company Overview
History and Background
Venus Concept Inc. was founded in 2009 and focuses on developing, commercializing, and delivering non-invasive medical aesthetic technologies and aesthetic subscription programs. They aim to provide solutions for aesthetic professionals and patients.
Core Business Areas
- Aesthetic Device Sales: Development and sale of medical aesthetic devices utilizing various energy-based technologies like RF, laser, and IPL. Generate revenue from direct sales to clinics and spas.
- Aesthetic Subscription Program: Subscription-based service offering aesthetic treatment consumables and marketing support to aesthetic clinics, providing recurring revenue.
Leadership and Structure
The company has a CEO, CFO, and a board of directors. They operate with functional departments including R&D, sales, marketing, operations, and finance. As of 2023 Rajiv De Silva is the Chairman of the Board and CEO. Domenico Della Penna is CFO.
Top Products and Market Share
Key Offerings
- Venus Bliss: A diode laser system for non-invasive lipolysis, reducing fat and cellulite. Market share data is not publicly disclosed. Key competitors include BTL Aesthetics, Allergan Aesthetics (CoolSculpting).
- Venus Legacy: A non-invasive body contouring and skin tightening device using (MP)2 technology (Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields). Market share data is not publicly disclosed. Key competitors are BTL Aesthetics, Allergan Aesthetics (CoolSculpting).
- Venus Versa: A multi-application platform offering a variety of aesthetic treatments, including photorejuvenation, acne treatment, hair removal, and skin resurfacing. Competitors include Cynosure, Cutera, and Lumenis. Market share data is not publicly disclosed, but Venus Versa is a significant revenue generator.
- Venus Viva: A fractional RF system for skin resurfacing and wrinkle reduction. Key competitors include Alma Lasers, Lumenis, and Cutera. Market share data is not publicly disclosed.
Market Dynamics
Industry Overview
The medical aesthetics market is growing, driven by increasing demand for non-invasive cosmetic procedures. The industry is characterized by technological innovation and competition among device manufacturers and service providers.
Positioning
Venus Concept is positioned as an innovative provider of cost-effective aesthetic solutions, targeting a broad range of aesthetic practitioners.
Total Addressable Market (TAM)
The global medical aesthetics market is projected to reach over $20 billion by 2028. Venus Concept is positioned to capture a share of this growing market through its device sales and subscription program.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Subscription-based business model
- Global presence
- Wide range of applications
Weaknesses
- High marketing and sales expenses
- Dependence on third-party manufacturers
- Limited profitability
Opportunities
- Expanding into new geographic markets
- Developing new applications for existing technologies
- Acquiring complementary businesses
- Growing aesthetic subscription program
Threats
- Intense competition
- Technological obsolescence
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- CYNO
- ALMA
- BTL Industries
Competitive Landscape
Venus Concept competes on technology, price, and customer service. The company's subscription program provides a competitive advantage by offering recurring revenue and customer loyalty.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been moderate with increase in revenues in the recent years
Future Projections: Future growth is expected to come from expanding sales of existing products, launching new products, and growing the subscription program.
Recent Initiatives: Recent initiatives include expanding the sales force, introducing new marketing campaigns, and developing new products.
Summary
Venus Concept shows promise with innovative technology and a recurring revenue model through its subscription program. However, it faces challenges related to profitability, competition, and high operating expenses. Successfully managing costs and expanding its market presence are critical for sustained growth. Monitoring technological advancements and adapting to regulatory changes are also essential for long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Company filings (SEC)
- Industry reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share data is often estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Venus Concept Inc
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2012-11-05 | CEO & Director Mr. Rajiv Kanishka Liyanaarchchie De Silva | ||
Sector Healthcare | Industry Medical Devices | Full time employees 292 | Website https://www.venus.ai |
Full time employees 292 | Website https://www.venus.ai |
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, a portable and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF combined with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, flanks, back, and thighs in individuals with a body mass index BMI of 30 or less; Venus Glow, a Motorized dermabrasion device used to improve skin appearance; and NeoGraft, a hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.